Glaukos Corp (NYSE:GKOS) shares hit a new 52-week high on Tuesday . The company traded as high as $75.82 and last traded at $75.20, with a volume of 21296 shares trading hands. The stock had previously closed at $73.08.

A number of research analysts have weighed in on GKOS shares. Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a report on Monday, March 4th. BTIG Research started coverage on Glaukos in a research note on Friday, March 8th. They issued a “neutral” rating and a $66.02 target price for the company. Stephens raised their target price on Glaukos from $70.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, February 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $80.00 target price on shares of Glaukos in a research note on Thursday, February 28th. Finally, Stifel Nicolaus raised their target price on Glaukos from $58.00 to $68.00 and gave the stock a “positive” rating in a research note on Thursday, February 28th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $68.50.

The company has a market capitalization of $2.64 billion, a PE ratio of -203.11 and a beta of 1.63.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, February 27th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.17. Glaukos had a negative return on equity of 8.24% and a negative net margin of 7.14%. The business had revenue of $54.08 million during the quarter, compared to the consensus estimate of $49.60 million. During the same period last year, the company earned $0.03 EPS. The company’s revenue for the quarter was up 29.8% on a year-over-year basis. On average, equities analysts anticipate that Glaukos Corp will post -0.33 EPS for the current fiscal year.

In other Glaukos news, CFO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $70.03, for a total value of $350,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Chris M. Calcaterra sold 90,000 shares of Glaukos stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $67.69, for a total value of $6,092,100.00. Following the completion of the transaction, the chief operating officer now directly owns 193,344 shares of the company’s stock, valued at $13,087,455.36. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in Glaukos by 14.3% during the second quarter. Bank of New York Mellon Corp now owns 171,070 shares of the medical instruments supplier’s stock worth $6,952,000 after purchasing an additional 21,420 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Glaukos by 96.2% during the third quarter. JPMorgan Chase & Co. now owns 90,688 shares of the medical instruments supplier’s stock worth $5,886,000 after purchasing an additional 44,470 shares during the last quarter. Prudential Financial Inc. purchased a new stake in Glaukos during the third quarter worth approximately $203,000. AXA purchased a new stake in Glaukos during the third quarter worth approximately $344,000. Finally, FMR LLC lifted its stake in Glaukos by 16.2% during the third quarter. FMR LLC now owns 1,227,430 shares of the medical instruments supplier’s stock worth $79,660,000 after purchasing an additional 171,268 shares during the last quarter.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/glaukos-gkos-sets-new-1-year-high-at-75-82/2902621.html.

About Glaukos (NYSE:GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Recommended Story: Momentum Investing

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.